Cipla, Iceland#39;s Alvotech ink pact to sell biosimilar Adalimumab in emerging markets

Cipla, Iceland#39;s Alvotech ink pact to sell biosimilar Adalimumab in emerging markets As per the partnership, Alvotech will be responsible for development and supply of the product, whereas Cipla will be responsible for registration and commercialisation of the product

No comments:

Post a Comment